Gentian Lluri
Interventional Cardiology · Los Angeles, CANPI 1154595346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Abbott at 40.8% of the total. Reporting peaked in 2022 at $616 and has fallen 83.4% since, to $102 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 28 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$445
- Actelion Pharmaceuticals US, Inc.$387
- Edwards Lifesciences$242
- Medtronic$17
Across 4 payments — averaging $7449.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$30K
What the payments were for
- Food & beverage$99191%
- Education$1009%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $445 |
| Actelion Pharmaceuticals US, Inc. | 13 | $387 |
| Edwards Lifesciences | 6 | $242 |
| Medtronic | 1 | $17 |
How this compares
$1,091 in reported general payments places this provider in the 15th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 93 | $132,405 |
| EntrestoSacubitril/Valsartan | 32 | $45,619 |
| XareltoRivaroxaban | 26 | $38,860 |
| BrilintaTicagrelor | 11 | $11,931 |
| CrestorRosuvastatin Calcium | 18 | $9,884 |
| Sildenafil Citrate | 13 | $5,307 |
| Rosuvastatin Calcium | 110 | $3,038 |
| Atorvastatin Calcium | 163 | $1,904 |
| Bumetanide | 12 | $1,748 |
| Losartan Potassium | 132 | $1,722 |
| Carvedilol | 117 | $1,369 |
| Amlodipine Besylate | 161 | $1,200 |
| Metoprolol Succinate | 64 | $1,016 |
| Hydralazine Hcl | 65 | $783 |
| Metoprolol Tartrate | 104 | $701 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Los Angeles
- Evan ZahnLos Angeles$632K
- Steven BursteinLos Angeles$352K
- Jubin JosephLos Angeles$217K
- Ali NsairLos Angeles$162K
- Ray MatthewsLos Angeles$159K
- Daniel AsemotaLos Angeles$155K
- Christina EconomidesLos Angeles$150K
- Aakriti GuptaLos Angeles$139K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.